Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
- Written by PR Newswire
 |
- RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date.
- Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.
MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly...
